COVID Pill Tracker By Biomedical_trader Oct 19, 2020 Merck / Molnupiravir First Enrollment https://clinicaltrials.gov/ct2/show/NCT04575597 Nov 27, 2020 Revive Therapeutics / Bucillamine First Enrollment https://revivethera.com/2020/10/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19/ Period: Jan 1, 2021 to Jul 7, 2021 Alpha and Beta Variants Dominant https://www.wsj.com/articles/how-the-u-k-became-world-leader-in-sequencing-the-coronavirusgenome-11612011601 Mar 25, 2021 Netherlands scientists discover antiviral mechanisms relevant to Bucillamine https://www.liebertpub.com/doi/full/10.1089/ars.2020.8247 Apr 15, 2021 Merck scraps lead candidate to focus on Molnupiravir in high risk non-hospitalized patients https://www.fiercebiotech.com/biotech/merck-cans-one-covid-19-drug-scraps-a-clinical-trial-another Apr 28, 2021 Atea Pharmaceuticals / AT-527 First Enrollment https://cen.acs.org/pharmaceuticals/drug-development/Roche-partners-Atea-COVID-19/98/i43 Period: Jul 7, 2021 to Jan 1, 2022 Delta Variant Dominant https://www.cnbc.com/2021/07/07/cdc-data-shows-delta-is-now-the-dominant-covid-variant-in-the-us.html Aug 20, 2021 Pfizer / Ritonavir First Enrollment https://clinicaltrials.gov/ct2/history/NCT04960202?A=1&B=2&C=merged#StudyPageTop Oct 1, 2021 Merck / Molnupiravir High Risk Trial Completion https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ Oct 31, 2021 Revive Therapeutics / Bucillamine Primary Completion (Published Estimate) https://clinicaltrials.gov/ct2/show/NCT04504734 Nov 5, 2021 Pfizer / Ritonavir High Risk Trial Completion https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate Nov 17, 2021 Atea Pharmaceuticals / AT-527 Primary Completion (Published Estimate) https://clinicaltrials.gov/ct2/show/study/NCT04889040
